Specifically, it has been demonstrated that the upregulation of SHH and GLI1 expression in AML cells results in aberrant activation of the Hh pathway, particularly in CD34+ AML cells that are resistant to chemotherapeutic agents (124). This evidence concerns the gene GLI1 and acute myeloid leukemia.